Ligand id: 7648

Name: apatinib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 90.7
Molecular weight 397.19
XLogP 4.73
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Apatinib is approved in China for the treatment of patients with non-small-cell lung cancer and gastric cancer, notably being the first tyrosine kinase inhibitor approved for gastric cancer. Apatinib is being assessed in clinical trials as a treatment for metastatic gastric carcinoma, metastatic breast cancer and advanced hepatocellular carcinoma. Click here to view ClinicalTrials.gov's currently registered trials evaluating this compound. Apatinib has shown encouraging results in Phase I/II trials [1] across a range of malignancies.
Mechanism Of Action and Pharmacodynamic Effects
Apatinib inhibits VEGF-induced endothelial cell migration and proliferation, and thus inhibits the angiogenesis essential for tumour growth and survival. Apatinib also appears to overcome multi-drug resistance (MDR) in certain tumour cells, by inhibiting the efflux mechanism of the MDR associated transporters ABCB1 and ABDG2, towards conventional antineoplastic agents [2].